Health Chat Transcripts
Mission Statement
As part of the Cleveland Clinic’s Neurological Institute, the Mellen Center for Multiple Sclerosis offers state-of-the-art resources to provide the most advanced specialized care, supported by an extensive program of research and education. The Mellen Center is the largest and most comprehensive program for MS care and research worldwide, managing more than 20,000 patient visits every year. Basic and clinical research conducted at Cleveland Clinic sheds new light on MS every year.
The center’s mission statement is guided by these fundamental principles:
- To provide you and your family with compassionate, comprehensive, innovative and technologically advanced care of the highest quality.
- To conduct clinical and basic research of national and international distinction.
- To educate clinicians, academicians, investigators and allied health care providers about MS and to promote the education of our patients, their families and the general public about the disease.
News from the Mellen Center
- »Dr. Jeffrey Cohen discusses his stem cell research that is helping treat multiple sclerosis
- »Dr. Rudick - Overview of MS and the Mellen Center
-
- »Clinical Trials Using Adult Stem Cells to Treat MS
The Cleveland Clinic, University Hospitals Seidman Cancer Center and Case Western Reserve University are collaborating on a one-of-a-kind clinical trial in the United States, designed to treat, or even reverse, the debilitating effects of multiple sclerosis by using a patient's own adult stem cells.
View a full description of the mellen center ms stem cell trial
- »Valet Parking Available at Mellen Center
Valet service will be available to visitors coming to the Mellen Center starting Monday, June 27th. The valet will be available from 7:30 a.m. - 5:30 p.m.
If you have any questions, you can contact the parking services office at 216.444.2255.
- »Cleveland Clinic multiple sclerosis patients got engaged during a treatment session
- »Multiple Sclerosis: Taking Control of Spasticity
View a series of videos from the International Organization of Multiple Sclerosis Rehabilitation Therapists (IOMSRT) about taking control of Spasticity.
- »Hip Flexion Clinical Trial Needs Volunteers
A new study being conducted by Dr. Francois Bethoux at Cleveland Clinic’s Mellen Center for Multiple Sclerosis, and funded by the National MS Society, is investigating the use of a new device that may help ambulatory MS patients improve their walking abilities.
Volunteers ages 18-60 who have MS and difficulty walking due to weakness of their hip flexor muscles are invited to participate in the study. The purpose of the study is to evaluate the effectiveness of a hip flexion assist device (HFAD) on gait performance. The device is a brace that can be worn comfortably and discretely under clothing.
- »Investigational Oral Compound to Treat MS Effective, According to Phase III Trial
Two oral medications (pills) to treat multiple sclerosis have received recent attention, fingolimod (also known as FTY720) and cladribine. These are not pill forms of medications already-approved for MS (Avonex, Betaseron, Copaxone, Extavia, Novantrone, Rebif, and Tysabri) but are new medications.
- »Mellen Center receives large grant from the National MS society to perform a study of CCSVI in MS patients
The Mellen Center Staff, under the direction of Dr. Robert J. Fox, our medical director, recently received an important grant from the National MS society to study ‘chronic cerebrospinal venous insufficiency’ (CCSVI), a new theory of what causes MS. The project will evaluate individuals with MS and compare their ultrasound and MR venography results with those of healthy controls and individuals with other neurological and autoimmune disorders. We are pleased to have this opportunity to scientifically and objectively evaluate this possible link between multiple sclerosis and the blood flow out of the brain and spinal cord.
- »Gilenya, an oral medication was approved by the US FDA to treat relapsing forms of MS
Gilenya is the first approved oral disease modifying treatment for MS. Combined data from a Phase II study and two Phase III trials showed that Gilenya reduces relapses, disability progression, MRI lesion activity, and brain atrophy progression (loss of brain tissue).
Read the full story on Gilenya for Multiple Sclerosis
MS in Focus - Issue 16
- »Doctor Challenges Cause Of MS And Treatment
One day 7 years ago, after a long walk with his dog along the Hudson River in Manhattan, Marc Stecker noticed he was limping. Not long after, he was diagnosed with multiple sclerosis.
